TITLE

GFP-expressing influenza a virus for evaluation of the efficacy of antiviral agents

AUTHOR(S)
Kim, Jin; Park, Sehee; Lee, Ilseob; Lee, Sangmoo; Shin, Saem; Won, Yongkwan; Hwang, Min-Woong; Bae, Joon-Yong; Heo, Jun; Hyun, Hye-Eun; Jun, Hyejin; Lim, Soon; Park, Man-Seong
PUB. DATE
April 2012
SOURCE
Journal of Microbiology;Apr2012, Vol. 50 Issue 2, p359
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
74603418

 

Related Articles

  • New neuraminidase inhibitors for influenza: Current and potential therapeutic roles. Gonzalez, III, Luis S. // Formulary;Oct2000, Vol. 35 Issue 10, p812 

    Reports on the development of antiviral agents, zanamivir and oseltamivir, for the treatment of influenza. Existing antiviral agents for influenza; Specific activity of the agents against influenza virus neuraminidase; Role of neuraminidase in influenza virus replication; Influenza virus A and...

  • Recent Developments in Anti-influenza A Virus Drugs and Use in Combination Therapies. Kaihatsu, Kunihiro; Barnard, Dale L. // Mini-Reviews in Organic Chemistry;Feb2012, Vol. 9 Issue 1, p3 

    The pandemic potential of influenza viruses has engaged a large portion of the antiviral drug discovery research community in the development of numerous antiviral agents, with the ultimate goal to supplement effective immunization when new strains arise, especially after an antigenic shift....

  • Avian Influenza Poses Threat. Hayney, Mary S. // Journal of the American Pharmacists Association: JAPhA;Sep/Oct2005, Vol. 45 Issue 5, p633 

    Discusses the threat of avian influenza virus to humans. Determinants of the influenza virus; Plans for the pandemic outbreak of the virus; Role of anti-viral agents against the disease.

  • Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice. Park, Sehee; Kim, Jin Il; Lee, Ilseob; Lee, Sangmoo; Hwang, Min-Woong; Bae, Joon-Yong; Heo, Jun; Kim, Donghwan; Jang, Seok-Il; Kim, Hyejin; Cheong, Hee Jin; Song, Jin-Won; Song, Ki-Joon; Baek, Luck Ju; Park, Man-Seong // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Antiviral drugs are being used for therapeutic purposes against influenza illness in humans. However, antiviral-resistant variants often nullify the effectiveness of antivirals. Combined medications, as seen in the treatment of cancers and other infectious diseases, have been suggested as an...

  • Update: Influenza Activity--United States, 1999-2000 Season.  // MMWR: Morbidity & Mortality Weekly Report;1/28/2000, Vol. 49 Issue 3, p53 

    Summarizes influenza activity in the United States during October 3, 1999 to January 15, 2000. Predominant type of influenza virus; Characteristics of influenza viruses; Antiviral agents use to treat influenza.

  • Are the new antivirals really better? Lavoie, Suzanne R.; Starr, Stuart E. // Patient Care;2/29/1996, Vol. 30 Issue 4, p61 

    Evaluates the effectiveness of medicine used to treat viral diseases. Safety, efficacy and cost effectiveness of antiviral agents; Chemotherapeutic regimen for some viral diseases; Includes chickenpox; Herpes simplex; Influenza.

  • Two new weapons battle influenza. Cerrato, Paul L.; Rowell, Nancy // RN;Sep99, Vol. 62 Issue 9, p99 

    Cites the potential of an experimental vaccine and an antiviral drug to prevent influenza. Description of FluMist, an attenuated influenza virus vaccine available as a nasal spray; Efficacy of antiviral zanamivir in preventing febrile upper respiratory infections.

  • Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza A and B Virus Infections. Monto, A.S.; Fleming, D.M.; Henry, D.; de Groot, R.; Makela, M.; Klein, T.; Elliott, M.; Keene, O.N.; Man, C.Y. // Journal of Infectious Diseases;8/1/99, Vol. 180 Issue 2 

    Examines the efficacy and safety of neuraminidase inhibitor Zanamivir in the treatment of influenza A and B infections. Clinical manifestations on influenza; Efficacy of Zanamivir in reducing the duration and symptomatic effect of influenza; Advantage of Zanamivir over antiviral agents.

  • BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. Shin-Ru Shih; Jim-Tong Horng; Poon, Leo L. M.; Tzu-Chun Chen; Jiann-Yih Yeh; Hsing-Pang Hsieh; Sung-Nain Tseng; Chiayn Chiang; Wan-Ling Li; Yu-Sheng Chao; Hsu, John T.-A. // Journal of Antimicrobial Chemotherapy (JAC);Jan2010, Vol. 65 Issue 1, p63 

    Objectives: The emergence of oseltamivir-resistant viruses raised the global threat with regard to influenza virus infection. To develop alternative antiviral agents against influenza virus infection is significant and urgent.

  • Long term study results of Gilead's Hepsera show suppression of hepatitis B.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p10 

    Reports on the outcome of the clinical study of Hepsera, an oral antiviral agent developed by Gilead Sciences Inc. for patients with hepatitis B virus. Presentation of the clinical study of Hepsera; Patients enrolled in the study; Evaluation of the safety and efficacy of the drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics